NeuroVive appoints Daniel Schale as Director of Communications
Lund 4 October 2017 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced the appointment of Daniel Schale as Director of Communications. Daniel will report to CFO Catharina Johansson.
Daniel Schale will be responsible for the company’s communications, media relations and public affairs. Daniel has ten years of experience in PR and communications, in recent years with special focus on pharmaceuticals, biotech and life science. Daniel holds an M.Sc. in Economics from Lund University.
”The recruitment of Daniel to NeuroVive is very important to us and the development of our company. Communication is key for us, both towards investors and other stakeholders, such as patients, healthcare professionals, governmental and regulatory bodies, scientists and the public. We will continue to prioritize communication regarding our projects and our business model, but we also want to increase the focus on the purpose of our research and development, as well as the diseases we aim to provide novel treatment opportunities for”, commented Catharina Johansson, CFO, NeuroVive.
Daniel joins NeuroVive from a role as senior corporate communications and public affairs advisor with the Swedish PR-firm Aspekta. Having been responsible for clients in the pharmaceutical and life science industries, Daniel has worked with lobbying, advocacy and disease awareness, as well as market access communications.
”NeuroVive is an exciting company with several interesting projects. It is very stimulating to start to work with further strengthening, broadening and clarifing the company’s communication towards investors and other stakeholders. With my background in public affairs and lobbying, I hope to contribute towards NeuroVive taking on a bigger role in the public debate, for instance on issues related to orphan drugs and therapeutic areas of importance to the company”, said Daniel Schale, Director of Communications, NeuroVive.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
For further information, please contact:
Daniel Schale, +46 (0)46-275 62 21, email@example.com.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund
Tel: 046-275 62 20, Fax: 046-888 83 48